Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 6,000 shares of the company’s stock in a transaction dated Wednesday, September 21st. The shares were sold at an average price of $115.03, for a total transaction of $690,180.00. Following the completion of the transaction, the director now owns 193,142 shares in the company, valued at $22,217,124.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Stryker Corp. (NYSE:SYK) opened at 116.44 on Thursday. Stryker Corp. has a 12 month low of $86.68 and a 12 month high of $123.55. The firm has a market cap of $43.58 billion, a P/E ratio of 27.45 and a beta of 0.71. The stock’s 50 day moving average is $114.36 and its 200 day moving average is $112.81.

Stryker Corp. (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 21st. The medical technology company reported $1.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.33%. The company earned $2.84 billion during the quarter, compared to analyst estimates of $2.79 billion. Equities research analysts expect that Stryker Corp. will post $5.76 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be issued a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 1.31%. The ex-dividend date of this dividend is Wednesday, September 28th. Stryker Corp.’s payout ratio is 35.85%.

Several equities analysts recently commented on SYK shares. Canaccord Genuity restated a “buy” rating and issued a $130.00 price target on shares of Stryker Corp. in a research note on Sunday, July 24th. Credit Suisse Group AG reiterated an “outperform” rating and set a $124.00 price objective (up from $110.00) on shares of Stryker Corp. in a research note on Tuesday, July 19th. Brean Capital reiterated a “buy” rating and set a $125.00 price objective (up from $121.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Zacks Investment Research upgraded shares of Stryker Corp. from a “hold” rating to a “buy” rating and set a $130.00 price objective on the stock in a research note on Tuesday, June 21st. Finally, JPMorgan Chase & Co. reiterated a “hold” rating and set a $119.00 price objective on shares of Stryker Corp. in a research note on Friday, July 22nd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. Stryker Corp. has an average rating of “Hold” and a consensus target price of $114.91.

Hedge funds have recently modified their holdings of the company. LSV Asset Management purchased a new stake in shares of Stryker Corp. during the second quarter valued at about $107,000. Global X Management Co. LLC raised its stake in shares of Stryker Corp. by 235.8% in the second quarter. Global X Management Co. LLC now owns 994 shares of the medical technology company’s stock valued at $119,000 after buying an additional 698 shares in the last quarter. Carroll Financial Associates Inc. raised its stake in shares of Stryker Corp. by 78.0% in the second quarter. Carroll Financial Associates Inc. now owns 1,086 shares of the medical technology company’s stock valued at $130,000 after buying an additional 476 shares in the last quarter. CWM LLC purchased a new stake in shares of Stryker Corp. during the second quarter valued at about $150,000. Finally, SevenBridge Financial Group LLC purchased a new stake in shares of Stryker Corp. during the second quarter valued at about $197,000. 75.49% of the stock is owned by institutional investors and hedge funds.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.